Julio Gay-Ger, an industry and Eli Lilly veteran, shares how he is leveraging on his 23 years of experience managing Lilly affiliates in LATAM to deliver on Lilly’s objective to position China as the second-largest affiliate for the Group; the significance of their recent February 2019 launch of diabetes treatment Trulicity®, a weekly GLP-1 receptor agonist that is already the category leader in key markets like the US, Japan and Germany; and the bolder and smarter ways in which Lilly is conducting external partnerships in China.
China, while the second-largest market in the world, is still not a mature market. Most of the multinational pharma affiliates here have only been fully present in China for a maximum of 30 years. This is a very short amount of time
